MMP9 Antibody, Clone L51/82: APC

Cannot supply to this region.

SKU:: SMC-396D-APC
Additional Names:: MMP9, MMP-9, Matrix metalloproteinase 9, CLG4B, 82kDa matrix metalloproteinase-9, Collagenease type 4 beta, GELB, Macrophage gelatinase, MANDP2, Type V collagenase, 92 kDa gelatinase, 92 kDa type IV collagenase, Gelatinase B
Application:: Flow Cytometry, IHC, WB, IF, ICC, IP
Concentration:: 1 mg/ml
Species Reactivity:: Rat
Purification:: Protein G Purified
Storage Conditions:: See Manual
Supplier:: StressMarq Biosciences
Host:: Mouse
Reactivities:: Human, Mouse, Rat
ABP:: IMP-GEN-2015-06 < 10% Serum <100ml
Buffer:: 95.46mM Phosphate, 2.48mM MES and 2mM EDTA
Immunogen:: Fusion protein amino acids 1-708 (full length) of rat MMP9
Clone:: L51/82 (Formerly sold as S51-82)
Uniprot:: P50282
Synonyms:: 92 kDa gelatinase;92 kDa type IV collagenase;92-kDa type IV collagenase;gelatinase B;GELB;matrix metalloproteinase 9 (gelatinase B, 92-kDa type IV collagenase);matrix metalloproteinase-9;MMP-9
Extra Details:: Matrix metalloproteinase 9 (MMP9) is an extracellular endopeptidase involved in the degradation of the extracellular matrix (ECM). In the central nervous system, MMP9 regulates synaptic remodeling, neuroinflammation, and blood-brain barrier permeability. Elevated MMP9 activity has been observed in neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). MMP9 contributes to neuronal injury by promoting ECM breakdown, facilitating leukocyte infiltration, and activating pro-inflammatory cytokines. MMP9 is synthesized as a latent proenzyme and requires proteolytic cleavage for activation. Its expression is tightly regulated at the transcriptional level and by endogenous inhibitors such as TIMPs (tissue inhibitors of metalloproteinases). Targeting MMP9 activity offers therapeutic potential for preserving blood-brain barrier integrity, reducing neuroinflammation, and limiting tissue damage in neurodegenerative conditions.

Shipping Conditions:: Blue Ice